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ABSTRACT
Objective: This study evaluated the relationship between marijuana use and sexually transmitted
diseases in pregnant women.
Methods:A retrospective review of clinic records over a 12-1/2 month period identified all women
entering prenatal care. Eighty-six women using no illicit substance other than marijuana were
compared to 441 drug-free women. The prevalence of gonorrhea, chlamydia, syphilis, human
immunodeficiency virus, hepatitis B surface antigen, human papilloma virus, and herpes was as-
certained.
Results: No significant differences were found in the prevalence of any single sexually transmit-
ted disease between pregnant women who used marijuana and drug-free pregnant women. When
the presence of one or more sexually transmitted disease was considered, again no difference was
found.
Conclusion: Marijuana use was not associated with sexually transmitted disease in pregnant
women. Infect. Dis. Obstet. Gynecol. 8:155-157, 2000. (C)2000 Wiley-Liss, Inc.
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arijuana is the illicit drug used most com-
monly during pregnancy. 1,e Gravidas who
use marijuana differ from women who do not:
they are more likely to be African-American, less
educated, unmarried, or poor.
3 Use of other sub-
stances, including alcohol, tobacco, and other illicit
drugs is more likely.4,s Aspects of pregnancy out-
come, including gestational age at delivery and in-
fant birth weight, have received considerable
evaluation.3-s
The relationship, if any, between marijuana use
and sexually transmitted diseases has received
little attention. A cross-sectional study of sexually
active adolescents attending a general health orga-
nization teen clinic found a two-fold increase in
sexually transmitted diseases in those patients who
used marijuana at least once per week.6 informa-
tion concerning the relationship between sexually
transmitted diseases, pregnancy, and marijuana use
was found in a report primarily evaluating fetal
growth.4 Differences between the marijuana user
and control for the presence of either syphilis, gon-
orrhea, herpes, pelvic inflammatory disease or chla-
mydia infection did not exist. However, the criteria
for diagnosis or testing schedules were not pro-
vided. Another study, also addressing low birth
weight, found no difference in isolation of C. tra-
chomatis between patients who used or did not use
marijuana. 7 Other sexually transmitted diseases
were not considered.
Our population previously has been identified
as having significant risk for both sexually trans-
mitted infections and marijuana use.8,9 In this ret-
rospective cohort study among pregnant women we
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evaluated the relationship between marijuana use
and sexually transmitted infection.
SUBJECTS AND METHODS
Between January 1, 1997 and January 15, 1998, 557
women who have been previously characterized
entered prenatal care at an inner-city prenatal pro-
gram serving poor women. 8,9 On initial visit pa-
tients provided a comprehensive history and were
questioned about use of alcohol, tobacco, mari-
juana, cocaine, and other illicit drugs. Patients sub-
mitted urine samples that were screened for mari-
juana, cocaine, and other substances. Any patient
who provided a history of illicit substance abuse or
had a positive urine drug screen underwent
monthly urine retesting. At initial visit patients also
were screened with the following lab tests: vene-
real disease research laboratory result, hepatitis B
surface antigen, human inmunodeficiency virus
status (confirmed by Western blot), and DNA
probe for C. trachomatis and N. gonorrhea. A Pap
smear, evaluating the presence of human papilloma
virus, was obtained as well. Screens for syphilis,
HIV, gonorrhea, and chlamydia were repeated in
the third trimester. Any patients with signs or
symptoms of genital herpes were cultured for this
virus. Patients with condyloma acuminata also were
recorded, and were included in those reported with
human papilloma virus.
In order to limit the potential confounding ef-
fect of cocaine or other illicit substances, two
groups were selected for evaluation: 1) drug-free
patients with negative histories and negative urine
screens and 2) women who admitted to marijuana
use during pregnancy or screened positive for mari-
juana, but who denied and tested negative for
other illicit substances.
This research was approved by our institutional
review board. Bivariate data were analyzed using
Xz or Fisher’s exact test, as appropriate. If a sig-
nificant association was found, the magnitude also
was expressed with odds ratios and 95% confidence
limits. Continuous data were expressed as mean +
standard deviation, but compared using Wilcoxin
rank sums. Significance was set at 0.05. Study size
was determined assuming the prevalence of having
one or more sexually transmitted infections to be
20% in drug-free pregnant women and 40% in
marijuana-using patients. With [3 0.20 and ot
0.05, 46 patients in each group would be required.
TABLE I. Description of patients
Marijuana only Drug free
n 86 n 441 P
Age -> 20 years 50 (58%) 243 (55%) n.s.
Black 84 (98%) 433 (98%) n.s.
Parity > 56 (65%) 245 (56%) n.s.
an.s. not significant
RESULTS
Marijuana use was found in 104 (18.7%) of re-
viewed patients. Eighty-six were found to have
used no other illicit substance and constituted the
marijuana-only group. Sixteen patients provided a
positive history for marijuana use, but had negative
urine screens. Thirty-three women had positive
urine screens only. The remaining 37 patients had
positive histories and urine tests. The drug-free
group consisted of 441 women with both a negative
history and urine toxicology for illicit substances.
Patients in the two groups were similar with re-
spect to age and race (Table 1). The 86 marijuana-
only patients were 21.0 + 4.2 years vs. 21.1 + 4.4
years for drug-free women, P n.s. There was no
significant difference in the prevalence of multi-
parity. However, marijuana-using women were
more likely to have a history of a prior sexually
transmitted disease, 45% vs. 26%, P < 0.001, odds
ratio 2.3 (1.4- 3.7).
During pregnancy, the most common sexually
transmitted diseases were chlamydia and gonor-
rhea. No differences between the marijuana-only
and drug-free groups were found for any of the
reported sexually transmitted diseases (Table 2).
When the occurrence of any sexually transmitted
infection was considered, 21% of the marijuana-
using patients and 24% of the drug-free patients
were so identified. The difference was not statis-
tically significant.
DISCUSSION
Sexually transmitted diseases do not appear to be
present more often in pregnant women whose il-
licit drug use is limited to marijuana than in drug-
free women. The overall infection rate was not dif-
ferent. Differences for individual diseases also
appear to be absent, although sample size is clearly
inadequate to identify the small differences which
may be present. For example, 539 patients in each
group would need to be evaluated before the ob-
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TABLE 2. Occurrence of sexually transmitted
disease and marijuana use during pregnancy
Marijuana only Drug free
n 86 n 441 P
Gonorrhea 6 (7%) 15 (3%) n.s.
Chlamydia 13 (I 5%) 81 (18%) n.s.
Syphilis 2 (2%) 12 (3%) n.s.
HIV 0 (0%) 2 (I %) n.s.
HBsAg (I %) 0 (0%) n.s.
HPV 3 (3%) 8 (2%) n.s.
Herpes 0 (0%) 8 (2%) n.s.
Any sexually transmitted
disease 18 (2 I%) 104 (24%) n.s.
an.s. not significant
bHIV human immunodeficiency virus
CHBsAg hepatitis B surface antigen
dHPV human papilloma virus
served differences for gonorrhea (3% vs. 7%)would
have sufficient power to exclude type II error.
Sexually transmitted diseases are common in
our patient population. Disease prevalence is simi-
lar to that found in other reviews we have con-
ducted. Among non-cocaine-using control patients,
4% were found to have syphilis and 3% to have
gonorrhea.1 About 15% of pregnant women in our
program tested positive for chlamydia.
11 HIV, her-
pes, and hepatitis B are uncommon.8 We believe
the current findings are representative of our pa-
tients, and more specifically, the observations in
our control group are consistent with what was ex-
pected.
Limitations of the study include only a single
interview for substance abuse and only a single
urine screen for most patients. Screening and test
results from delivery are not reported. Frequency
or amount of drug use, an important parameter in
the report of Boyce et al.6 was not documented.
The inclusion of all users (including less frequent
users) may dilute a potential relationship. Another
limitation is the nature of the population reported.
Our study evaluated only women enrolled in pre-
natal care; the influence of absent prenatal care is
uncertain. Comparison to nonpregnant adolescents
is also problematic and extension to other groups
may be inappropriate.
Our study population carries significant risk for
sexually transmitted diseases, as expected, since
they are young and sexually active. The data rein-
force the prior, but limited, observation of lack of
differences between marijuana using and nonusing
prenatal patients as suggested by Zuckerman’s re-
port.
4 In our review, history of prior sexually trans-
mitted infection was observed more often in the
marijuana-using group as is consistent with prior
observations of nonpregnant adolescents.6 Never-
theless, when considering a pregnant population
such as the one we report, the conclusion we draw
is that marijuana use alone is unassociated with
sexually transmitted infection.
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